Mostrar el registro sencillo del ítem

dc.contributor.authorPalanques-Pastor, Tomás
dc.contributor.authorLópez-Briz, Eduardo
dc.contributor.authorPoveda Andrés, José Luis
dc.date.accessioned2020-07-10T20:35:45Z
dc.date.available2020-07-10T20:35:45Z
dc.date.issued2020
dc.identifier.urihttp://dx.doi.org/10.1136/ejhpharm-2020-002322en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12663/2033
dc.description.abstractIn December 2019, a cluster of patients with pneumonia of unknown cause was reported in Wuhan (China). After analysis of respiratory samples, scientists isolated a new virus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the outbreak of coronavirus disease 2019 (COVID-19). The virus spread rapidly with an increasing number of infected patients in multiple countries, and the World Health Organization (WHO) declared the disease pandemic. Since the start of the pandemic to the date of this report, more than 2 285 000 cases have been detected in 213 territories around the world and more than 155 000 people have died. COVID-19 is a zoonotic disease and person-to-person transmission occurs primarily via direct contact or through droplets spread by coughing or sneezing from an infected individual. The main signs and symptoms include fever (87.9%), dry cough (67.7%), fatigue (38.1%), sputum production (33.4%) and shortness of breath (18.6%). Approximately 13.8% of patients have severe disease (dyspnoea, respiratory frequency ≥30/min, blood oxygen saturation ≤93% and PaO2/FiO2 ratio 50% of the lung field within 24–48 hours) and 6.1% are critical (respiratory failure, septic shock and multiple organ dysfunction). Our hypothesis is the possibility of using the drug siltuximab in the management of patients with severe COVID-19 infection. Hence the main objective of our study was to explore the involvement of interleukin (IL) 6, the target of action of siltuximab, in SARS-CoV-2 infection.en_US
dc.languageEnglishen_US
dc.subjectCOVID-19en_US
dc.subjectCoronavirus Infectionsen_US
dc.subjectInfectious Diseasesen_US
dc.subjectBetacoronavirusen_US
dc.subjectSARS-CoV-2en_US
dc.subjectInterleukin-6en_US
dc.subjectInterleukinsen_US
dc.titleInvolvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19en_US
eihealth.countryOthersen_US
eihealth.categoryCandidate therapeutics RDen_US
eihealth.typePublished Articleen_US
eihealth.maincategorySave Lives / Salvar Vidasen_US
dc.relation.ispartofjournalEuropean Journal of Hospital Pharmacyen_US


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem